Evan Seigerman, an analyst from BMO Capital, has initiated a new Buy rating on Replimune Group (REPL).Stay Ahead of the Market:Discover ...

Oncology nurses can educate patients about the potential indications for oncolytic virus therapy and connect them to ...

It's not the first therapy in the oncolytic virus class to be approved around the world, as that accolade went to Amgen's Imlygic (talimogene laherparepvec), which was cleared by the FDA for the ...

Home » Oncolytic viruses deliver B7H3-targeting BiTE to the tumor site, enhancing antitumor T-cell immunity X Upgrade your daily dose of biopharma and medtech news ...

With its proprietary platform Invir.IO®, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. This press release contains ...

Oncolytic adenoviruses were designed to reach potent intratumoral T-cell activation via expression of bifunctional-T-cell ...

An international team of UK and US scientists has discovered that the activity of macrophages—a type of white blood cell that ...

Moreover, TILT’s oncolytic viruses encoding a variety of cytokines can be delivered either directly to tumors or intravenously, and have applicability across a wide range of cancer indications.

Delytact (teserpaturev) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) that was approved for marketing in Japan earlier this year, and received pricing approval in ...

PsiVac is set to end decades of disappointing data on oncolytic viruses with a radical new approach that upends conventional wisdom about the modality. Rather than engineer the viral genome ...

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on targeted immunotherapies, has priced its public offering of 5,000,000 shares of common stock at $0.85 ...

Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotechnology company focused on targeted immunotherapies, has priced its <a target= ...